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Diagnostic and Treatment Procedures Induced by 
Cervical Cancer Screening 
Marjolein van Ballegooijen, Marc A. Koopmanschap, Gerrit J. van 
Oortmarssen, J. Dik F. Habbema, Koos Th. N. Lubbe 
and Heleen M.A. van Agt 
The amount of diagnostic and treatment procedures induced by cervical cancer screening has been assessed 
prospectively and related to mortality reduction. Assumptions are based on data from Dutch screening 
programmes and on a scenario for future developments. With 5 invitations for screening, between ages 37-70 
every eight years, 13 deaths are avoided per million women per screening year. Each death avoided is balanced 
by 2800 preventive smears, 9 women referred to a gynaecology department and 4 minor treatment procedures 
(conserving treatment or exconisation). 25 invitations in a life-time avoids 27 deaths per million women per 
screening year but with 7300 preventive smears, 22 referrals and 8 small treatment procedures. Thus intensifying 
screening will not only result in diminishing returns of extra screening efforts, but also in increasing risk for 
women to undergo unnecessary (no invasive disease or death avoided) diagnostic and treatment procedures. The 
balance between beneficial and adverse effects deteriorates strongly when hysterectomies play an important part 
in the management of cervical intraepithelial neoplasia. 
EurJ Cancer, Vol. 26, No. 9, pp. 941-945,199O. 
INTRODUCTION 
THE APPROPRIATENESS of screening for cervical cancer should 
be balanced between beneficial health effects and adverse effects 
and costs. As the avoidance of death is the principal aim, most 
evaluations have concentrated on the relation between life-years 
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saved and costs, which shows a diminishing return for the extra 
efforts involved in screening women more frequently [l-3]. 
Although unnecessary referrals and diagnostic and local thera- 
peutic procedures are often discussed as the major adverse effect 
of cervical cancer screening, reports on this effect are scarce. 
Treatments of advanced cancer will be reduced by early detec- 
tion. But due to follow-up of false positive smears and of 
lesions that would have regressed spontaneously, there will be a 
considerable increase in the number of diagnostic and minor 
therapeutic procedures. We have assessed this increase and 
related it to the number of life-years gained. 
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METHODS Table 1. Primary treatment procedures found (a) in eight Dutch 
Yield of early detection hospitals* in 1982-1986 and (b) in pilot region of Nijmegen in 
1981-1984 The effects of cervical cancer screening have been predicted 
by a mathematical model [4-6]. The model has been validated 
by analysing cervical cancer screening data from the British 
Columbia Cohort Study [7] and from pilot cervical cancer 
screening projects (1976-1985) in the Netherlands [8]. Both 
analyses led to similar conclusions [4]. Model-based analysis of 
the Dutch data led to the following estimates: (a) mean duration 
of the pre-clinical stages, 17 years and shortest at old ages; (b) 
regression rate of pre-invasive disease, 60% on average and 
highest at young ages; and (c) sensitivity of cervical cytology, 
70% for cervical intraepithelial neoplasic (CIN) III. 
<GIN III+ CIN III CIN IA 
Treatment (a) (b) (a) (b) (a) (b) 
None 
Conserving 
Exconisation 
Exconisation + 
hysterectomy 
ND 61% - - - - 
ND 10% 25% 28% - - 
ND 6% 64% 15% 38% 0% 
ND - 4% - 46% 50% 
With other assumptions (e.g. shorter duration, less regression 
or higher sensitivity) the observed Dutch screening results and 
incidence and mortality data could not be explained. The false 
positive rate, defined as the percentage of women in whom no 
CIN III or invasive cancer was found after an abnormal (at least 
moderate dysplasia) cervical smear, was 0.4%. This number has 
been used in our calculations. 
Hysterectomy 
Unknown 
Total no. 
ND 23% 7% 48% 16% 50% 
ND - - 9% - - 
66 663 46 24 2 
The validated model was used to simulate different screening 
policies in Dutch women during 1988-2015. Effects of screening 
occurring after 2015 have been taken into account. The popu- 
lation dynamics including deaths by causes other than cervical 
cancer have been incorporated into the model. The impact of 
cervical cancer screening before 1988 and of hysterectomies 
performed for reasons other than cervical cancer have also been 
taken into account. The population attendance rate has been 
assumed to be 65% on average, as observed in the Dutch pilot 
regions. Attendance decreases gradually for women over 50, to 
5 5% for women aged 70. 
*Academisch Medisch Centrum (Amsterdam), Medisch Centrum Alk- 
maar, Sint Franciscus Gasthuis Rotterdam, Ziekenhuis Leyenburg 
(Den Haag), Ikazia Ziekenhuis Rotterdam, RK Ziekenhuis Groningen, 
Catherina Ziekenhuis Eindhoven and Westeinde Ziekenhuis Den Haag. 
tWomen referred to gynaecology department for cervical cancer assess- 
ment, in whom no CIN or only CIN I/II was found. 
ND = no data. 
The model predicts the yearly number of smears, the yearly 
number of women diagnosed with CIN III, micro-invasive or 
cervical cancer by stage, the yearly number of women detected 
in whom no CIN III or worse is found during follow-up and the 
yearly number of women dying from cervical cancer. 
cervical cancer are summarised in Table 1. Conserving treat- 
ments (cryocoagulation, electrocoagulation, laser-evaporation 
and diathermic ablation) and exconisations are considered as 
minor treatment procedures. Table 1 also shows the treatment 
procedures used in eight Dutch hospitals of different size and 
in different regions during 1982-1986 and in the screening 
programme in the pilot region of Nijmegen during 1981-1984 
(office of Evaluation and Registration of Cervical Cancer). 
Effects were calculated compared with no early detection, 
which was also simulated and in which women are only detected 
by symptoms. In our model detection by symptoms occurs in 
stage IB at the earliest. 
Diagnosis and treatment 
Assessment of the number of women referred to a gynaecologi- 
cal department because of an abnormal cervical smear is of major 
importance when estimating the extent of diagnosis induced by 
screening. Referred women are supposed to undergo colposcopy 
at least once; most will have ectocervical biopsy and in some 
endocervical curettage will be done. We calculated the number 
of referred women from the predicted numbers of detected 
women. We assumed that all women with a histologically 
confirmed CIN III+ and 65% of the women followed up without 
a confirmed CIN III+ have been referred to a gynaecologist. 
The other 35% of the latter group is assumed to have had only 
repeat smears done by the general practitioner, as the data from 
the pilot regions indicate. In the pilot regions, a Pap-smear with 
moderate dysplasia was followed by a repeat smear within a few 
weeks. A smear with severe dysplasia or more led to immediate 
referral to a gynaecologist. 
The difference between the two data sets stresses the varia- 
bility in medical practice. Hysterectomies were more frequent 
in Nijmegen. The reasons for this were not investigated. Current 
developments towards less aggressive treatments are the further 
introduction of colposcopy in the assessment of suspected cervi- 
cal abnormalities and the decreasing rates for hysterectomies in 
general (there has been a more than 30% fall in the age group 
35-50 in the Netherlands since the late 1970s [9]). Hospital 
departments that reported data on their treatment procedures 
are probably departments that follow these developments more 
closely than average. The percentage for less aggressive pro- 
cedures in these hospitals, however, may be a good approxi- 
mation for future practice. So we used the hospital data for the 
assumptions on the average stage-specific treatment (Table 2). 
To calculate the numbers of primary treatment procedures, a 
schedule has been devised with a realistic frequency of treat- 
ments by stage of disease. This schedule was applied on the 
predicted numbers of detected women by stage. 
The possible treatment procedures in CIN and microinvasive 
As no detailed data were available on treatment procedures in 
women with less than CIN III we based our assumptions for 
this group on reported information and on interviews with 
expert gynaecologists. Of the women followed up in whom no 
CIN III or invasive disease is found, 70% are women without 
any neoplasia and 30% are women with CIN I/II (Office of 
Evaluation and Registration of Cervical Cancer and ref. 10). We 
assumed no treatment in the first group. The percentages for 
conserving treatment and exconisations in the group with CIN I 
or CIN II are based on the assumption that about 60% of these 
women are treated and 40% are strictly followed up by cytology. 
From the treated group 30% must (at least) have exconisation 
because in about 30% of the women with CIN the transformation 
zone and/or the lesion cannot entirely be seen with colpos~~py. 
So the percentage of conserving treatments in the women 
referred with less than CIN III is assumed to be 13% (30% x 
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Table 2. Assumptions used in prospective calculation of numbers of 
primay treatment procedures: percentages of primay treatment 
Table 3. Outcomes of three efficient cervical cancer early detection 
strategies per year per million women (prospective calculations) 
procedures by cervical cancer stage 
Treatment 
<GIN CIN IA IB II+ (by II+ (by 
III* III screening) symptoms) 
None (absence of CIN 81% - - - - - 
III) 
Conserving 
Conserving + 
exconisationt 
12% 24% - - - - 
1% 1% - - - - 
Exconisation 
Exconisation + 
hysterectomy 
6% 64% 38% - - - 
- 3% 62% - - - 
Hysterectomy - 8% 0% 90% 40% 
Primary radiation - - - 10% 60% 
Noprimarytreatment - - - - - 
(advanced disease) 
16% 
79% 
5% 
< CIN IIIt 
CIN III 
IA 
IB 
II+scr 
II+sympt 
Total 
No. of smears 
Deaths from cervical 
cancer 
Life-years lost 
No. of invitations* No early 
detection 
5 10 25 
140 299 745 0 
53 113 174 0 
5 6 5 0 
49 42 36 57 
1 1 1 0 
101 92 82 124 
349 554 1044 182 
36 800 78 700 196 100 0 
54 80 
(-l& (-Z) (-27) 
1172 989 854 1434 
(-262) (-446) (-580) 
*Women referred to a gynaecology department for cervical cancer 
assessment, in whom no CIN or only CIN I/II is found. *Per woman during her lifetime. 
tBecause of exconisations as re-treatment procedure assumed in 5% of tWomen with abnormal smears in whom no CIN or only CIN I/II is 
women who had conserving treatment. found. 
$Difference compared with no early detection. 
60% x 70%) and the percentage of exconisations to be 6% (30% 
x 60% x 30% [rounded]). Moreover, 5% of the women who 
had conserving treatment are assumed to have exconisation as 
re-treatment. 
Table 3 for the three detection strategies. All results are pre- 
sented per screening year, which means that the total outcomes 
and effects of screening in 1988-2015 have been divided by the 
number of screening years: 27 (i.e. “by year”). 
In the management of women with cervical cancer stage IA, 
at least an exconisation is assumed. In the Netherlands there 
is a consensus to avoid diagnosing stage IA without doing 
exconisation first. The two possible primary treatment pro- 
cedures in invasive cervical cancer stages IB or higher are 
radical surgery (with or without additional radiotherapy) and 
radiotherapy (alone). Data were studied from the eight hospitals, 
the Nijmegen region and from several other Dutch studies [ 11, 
121. All results were similar, and since no changes are expected 
in the near future, they were adopted. The difference in Table 2 
in the assumptions between stage II + detected by early detection 
and stage II+ detected by symptoms is based on the more 
favourable distribution over the stages IIA, IIB, III and IV in 
women detected by screening compared with those detected by 
symptoms [ 131. 
With more intensive screening a shift occurs in the detected 
precancers and cancers towards earlier stages. The total number 
of women followed-up increases significantly: from 349 (5 
invitations) to 1044 (25 invitations) per million women per year, 
mainly due to the increase in follow-up of women with no 
histological abnormalities or only CIN I or CIN II. With 
intensification of screening from 5 to 10 invitations, 184 
additional life-years are gained, while a further increase from 10 
to 25 invitations adds only 134 life-years more per million women 
per year. 
Intensifying the policy from 5 to 25 invitations per life-time 
causes a five-fold increase in the number of women referred 
(Table 4). This induces additional diagnostic and treatment 
procedures. More specifically, an increase from 5 to 25 invi- 
Screening policies 
We will discuss the results for three screening policies, with 
an increasing number of invitations for screening during a life- 
time: 5, 10 and 25. More invitations implies a shorter interval 
between successive invitations. These intervals are 8, 5 and 2 
years. The age-ranges are, respectively, 37-70,27-72 and 26-74 
years. This is a broad age range that does not correspond with 
most current practice. All three are so-called efficient screening 
policies. Policies are efficient when their distribution of screen- 
ings over the ages leads to the largest number of life-years gained 
at a certain level of costs, or conversely to the least costs for a 
certain number of life-years gained. Our study on the costs of 
cervical cancer screening is presented elsewhere [5]. 
Table 4. Effect on diagnostic and primary treatment procedures of 
three efficient cervical cancer early detection strategies (prospective 
calculations) 
RESULTS 
The stage distribution, number of smears, number of women 
followed up and mortality from cervical cancer are shown in 
No. of invitations* No early 
detection 
5 10 25 
Women referred +117t i266 +598 182 
Conserving treatments +25 +53 +106 0 
Exconisations 1-47 +96 +1s7 0 
Hysterectomies -2 -2 -3 72 
Primary radiotherapies -19 -26 -35 104 
Total +52 +121 +226 175 
*Per woman during her life-time. 
tPer year per million women (all ages), difference compared with no 
screening. 
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Fig. 1. Relationship between various beneficial and adverse effects 
of screening and intensity of screening, as represented by efficient 
cervical screening policies with 5, 10 and 25 invitations. Level of 
effects at 5 invitations is set to 100 (all lines go through origin). 
tations makes the number of conserving treatments rise from 25 
to 106 and exconisations rise from 47 to 157 per million women 
per year. 
The effect on the number of hysterectomies (total plus radical) 
of intensifying early detection efforts is modest. The reason is 
that the rise in the number of total hysterectomies caused by the 
increase in the number of women detected with CIN III (Table 
3) is neutralised by a decrease in radical hysterectomies caused 
by the fall in the number of women diagnosed with cervical 
cancer stage IB or higher. The number of primary radiotherapies 
falls as a result of the decrease in the number of diagnosed stages 
IB and higher. 
Tables 3 and 4 can be used to calculate the balance between 
the efforts and risks needed to prevent more deaths from cervical 
cancers by more intensive screening. With 5 invitations, for 
every death avoided, 2800 preventive Pap-smears, 9 referrals 
and 4 minor treatment procedures are needed. With 25 invi- 
tations, the corresponding figures are 7300,22 and 8. 
One reason for the deteriorating balance between beneficial 
and adverse effects is the strongly increased detection of women 
with no abnormalities or with lesions which are less advanced 
than CIN III (Table 3). The second reason is the increased 
detection of women with CIN III that would have regressed 
spontaneously. According to our predictions, this number would 
go from 32 to 77 to 121 per million women per year when 
Table 5. More aggressive treatment schedule in GIN and micro- 
invasive cervical cancer (percentagfs ofprimay treatment procedures 
by stage) 
Treatment <GIN III* CIN III IA 
None (absence of CIN III) 
Conserving 
Exconisation 
Exconisation + 
hysterectomy 
Hysterectomy 
55% - - 
10% 20% - 
10% 20% 5% 
- - 45% 
25% 60% 50% 
*Women referred to a gynaecology department for cervical cancer 
assessment, in whom no CIN or only CIN I/II is found. 
intensifying the policy from 5 to 10 to 25 invitations, respect- 
ively. The resulting additional treatments, a negative side-effect 
inherent to early detection of cervical cancer, do not result in 
avoided invasive disease or life-years gained. Adverse effects all 
increase at last two to three times as fast as the beneficial effects 
when intensifying the early detection policy (Fig. 1). 
Overall the diagnostic and treatment procedures induced by 
cervical cancer screening precede the mortality reduction by 
many years. Discounting of effects (when not considering the 
costs) is disputable. Nevertheless, when all effects are discounted 
with a rate of 5%, the ratios between unfavourable and favourable 
effects rise between 160% and 200%. There is not only a 
diminishing return for the extra efforts involved in screening 
women more frequently, but there is also an increasing risk for 
women to be referred and treated without having the benefit of 
invasive disease being presented. 
More aggressive earb treatment 
The results presented are very sensitive to the treatment 
procedures assumed in pre-invasive and micro-invasive stages, 
because of the large number of women concerned. Therefore 
we also made calculations for a more aggressive schedule, with a 
shift from minor treatment procedures to hysterectomies and 
less untreated women (Table 5). The results (Table 6) should 
be compared with those of Table 3. There is a sharp increase in 
the number of hysterectomies: for a limited early detection 
policy (5 invitations), a net decrease of 2 hysterectomies has now 
turned into a net increase of 48. For more intensive screening 
policies, this number increases nearly linearly, contrary to the 
number of deaths avoided. This is an important finding, as 
intensive policies are often advocated, for instance by the 
National Cancer Institute [ 141. 
The beneficial effects of screening are unaffected by the new 
assumptions, as survival is reported to remain excellent when 
more local treatment procedures are used in CIN and cervical 
cancer stage IA, provided the right selection criteria are used 
[15-171. The numbers and types of treatments without early 
detection remain unchanged, as no women with pre-invasive 
or micro-invasive disease are detected by symptoms in our 
calculations. 
DISCUSSION 
Complete data on treatments used in women with CIN I and 
CIN II are scarce. About 10% of women with CIN III in British 
Table 6. Prospective calculations with more aggressive treatment 
schedule: effects on quantity of diagnosis and primaty treatment 
resulting from three efficient early detection policies 
No. of invitations* No early 
detection 
5 10 25 
Women referred +117t +266 +598 182 
Conserving treatments +20 +42 +83 - 
Exconisations +20 +45 +86 - 
Hysterectomies +48 +103 +204 72 
Primary radiotherapies -19 -26 -35 104 
Total treatments +71 +164 +338 175 
*Per woman during her life-time. 
tPer year per million women, difference compared with no screening. 
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clinics [19-213 have total hysterectomies, and 60-70% have 
conserving treatment and 20-30% have exconisations. This is 
the opposite of that indicated by Dutch data. The possibility of 
a quality-bias in the British data cannot be ruled out. But if the 
average treatment schedule was as suggested by the British data, 
the numbers of conserving treatments and exconisations in 
Table 3 should be interchanged. The total level of adverse effects 
would be lower, but the pattern of increasing risks for women 
with increasingly intensive policies would remain unchanged. 
many referrals for diagnosis, conserving treatment procedures, 
exconisations and total hysterectomies are acceptable per radical 
treatment or death avoided. Our aim was not to provide an 
absolute answer to this question, but to provide the material 
required to compare different policies on these criteria. 
Results have been calculated for an average duration of 
preclinical disease of 17 years, a regression rate of 60% and a 
sensitivity of 70%. The calculations have been repeated for other 
values for duration, regression and sensitivity, which could still 
explain the results of screening in Canada and the Netherlands. 
The results were not affected substantially. In a sensitivity 
analysis we also studied the influence of possible changes in 
incidence and natural history on our results. In case of a higher 
cervical cancer incidence (in the absence of screening) in the 
future, all beneficial effects and some adverse effects increase 
proportionally. A smaller (or larger) number of spontaneously 
regressing lesions makes adverse effects decrease (or increase), 
leaving the number of deaths avoided unaltered. 
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